




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : A61L 2/18</p>	<p>A1</p>	<p>(11) International Publication Number: WO 98/22151 (43) International Publication Date: 28 May 1998 (28.05.98)</p>
<p>(21) International Application Number: PCT/US96/18604 (22) International Filing Date: 20 November 1996 (20.11.96) (71)(72) Applicant and Inventor: SHANBROM, Edward [US/US]; 2252 Liane Lane, Santa Ana, CA 92705 (US). (74) Agent: KIRCHANSKI, Stefan, J.; Graham & James L.L.P., 6th floor, 650 Town Center Drive, Costa Mesa, CA 92626 (US).</p>		<p>(81) Designated States: AU, CA, CN, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i></p>

(54) Title: TRACE CAPTURE IN BIOLOGICAL FLUIDS



(57) Abstract

A method for removing iodine from biological fluids and from various protein containing solutions to which elemental iodine has been added for disinfectant purposes is based on the use of a novel iodine absorbing agent. Free iodine and iodine loosely bond to proteins and biological structures can be rapidly removed by flowing liquid containing such proteins or biological structures through a porous polyvinyl-alcohol-acetal body. Solutions of blood proteins or fluids containing viable platelets can be successfully disinfected by adding an effective amount of active iodine to the solutions or fluids and subsequently passing the solutions or fluids through a porous polyvinyl-alcohol-acetal body to remove active iodine before any damage occurs to the proteins or platelets.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TRACE CAPTURE IN BIOLOGICAL FLUIDS

Field of the Invention

This invention relates to the removal of specific trace constituents, principally additives from a previous step, from biological fluids. Such fluids may be liquids or gases. Biological fluids, as the
5 term is used here refers to liquids or gases that are derived from a biological source, contain constituents that originated from a biological source, or that are supplied to a biological system. Without intending any limitation, such fluids would include, by way of example only,
10 blood and blood components, e.g. plasma, serum, clotting factors, etc., suspensions, solutions and emulsions of blood proteins, cells, etc., and nutrients for biological media, such as are used in the propagation of cell lines and air that is provided for breathing by humans, e.g. airline passengers. The invention may also be used
15 with laboratory and other animals. For example, air may be freed of viable pathogens for use by immunodeficient animals to prevent disease. Likewise, air may be pre-treated by means of this invention for use as a carrier for medication to the humans or other animals.

Again without limiting the scope of the field of the invention, the
20 present invention is expected, generally but not always, to be part of a process that includes a step in which one or more materials are added to the fluid to be treated and, after such addition, the fluid is caused to pass through a column, bed, filter, sponge or other solid configuration that acts to remove the residual of the additive, the
25 reaction product or the additive, or some other composition that results because the addition is made. It is known, however, that great care must be taken in preparing particulate filter beds, columns or

bodies, to prevent channeling within the bed, column or other body of particles and/or clogging of the filter by fines. Extraordinary care is required to prevent the escape of fines into the effluent treated fluid. The term "fines" is used in its conventional sense as applied to powders, granules, etc., i.e. fines are particles smaller than the size range of the great majority of the particles, e.g. particles of 0.1 to 1 micron that remain in a lot of particles having a nominal size range of 5 to 15 microns. An example, which is in no way limiting, that illustrates the application of the invention is a process in which a biocide is added to a biological fluid to kill bacteria, virus, etc., and thereafter the fluid is passed through a solid configuration as described wherein unreacted biocide, or reaction products of the biocide, or both, are removed by adsorption onto, absorption into or reaction with the solid. In most instances, it is to be expected that some amounts of other constituents of the fluid, e.g. water, etc., may also be removed as an incident to carrying out the process.

In a particularly important application, to which the present application is principally directed, the invention relates to the treatment of human or animal biological liquids, which may contain or carry cells. Liquid and cell-containing liquids from bio-engineering, genetic engineering, etc. are included in the meaning of the term biological liquids as used here.

Background of the Invention

The prior art generally is discussed in some detail in my United States Patents Nos. 5,360,605 and 5,370,869 along with specific discussions of the most relevant prior art references. It is sufficient to summarize the state of the art as follows: After at least three decades

of clear recognition of the serious and immediate need for methods to remove pathogenic virus, and other microbes, from blood, blood products, fractions and derivatives, and other biological liquids, the serious and immediate need remains unfilled. After nearly two
5 decades of near panic search for a solution to the aforementioned problem following the catastrophic spreading of AIDS via the blood banking system, the problem remains unsolved in need of an immediate solution on an increasingly urgent basis.

For the three decades referred to, indeed, for almost a century,
10 iodine has been known to all workers to be an effective contact biocide; indeed, iodine, in its various forms, is probably the most widely used and universally known biocidal material in medical history. A history of the relevant uses of iodine and the sources of iodine and iodine compounds is given in my aforesaid United States
15 Patents, the disclosure of which is incorporated herein by reference.

Rubinstein, U.S. Patent No. 5,185,371, discusses the long standing opposition to the use of iodine in blood which characterized, and still characterizes the general skill of the art. Referring to iodine and other oxidizers, Rubinstein summarizes the prior art in the
20 following terms: "None of these disinfectants have been applied to disinfecting blood products or tissue products. Such compositions in contact with blood and tissue products would cause one to expect resultant damage to the cells and tissue." Patent No. 5,185,371, col. 2, lines 43-48. Rubinstein asserts that the well-known disadvantages
25 of iodine as a biocide can be overcome by using iodine in isotonic solutions. Unfortunately, however, even Rubinstein's proposed use of isotonic iodine solutions alone has not solved the long standing and

urgent health care problem of infected blood and blood products.

At my direction, a comprehensive survey of the literature on the subject of iodine as a biocide was conducted. Following an analysis of the literature, I concluded, as had most other workers, that there was little hope that iodine or iodine compounds could be used effectively in the processing of blood. Notwithstanding the serious problems I set about to develop, if possible, methods for treating blood and blood constituents, plasma in particular, with iodine or iodine compounds to eliminate pathogens, e.g. HIV and hepatitis virus, without altering the biological material to be treated. Many methods have been developed. Much was learned about the use of iodine, in several forms, in biological materials. Several methods that initially appeared attractive, especially considering the overwhelming shadow of doubt that overlies the entire subject, were developed. Very importantly for current products and processes and future research, I have also developed general criteria that relate to the killing of virus in biological fluids, specifically in blood fractions and solutions containing blood constituents. While, it has not always been possible to quantify with exactitude the effect of the various parameters involved certain critical parameters have been discovered and defined.

There is some literature that makes reference to the effect of pH on the virucidal effectiveness of iodine. The problem, however, was defined only in broad terms that were not helpful. Such little definition of the problems as existed were unaccompanied by suggestion as to solving the problems involved in using iodine. It has been established that the virucidal effectiveness of iodine increases as pH decreases

below pH 7.0, and, significantly increases as the pH decreases below about 6.0. However, the combination of low pH and iodine alters many blood proteins, certain of the clotting factors in particular, rendering such processes unusable in most situations. This is especially true if iodine is added as Lugol's solution. The addition of comparable amounts of iodine as povidone iodine decreases the rate and/or amount of protein alteration, but also decreases the virucidal effectiveness of iodine on a short contact-time basis. Several approaches were taken to provide iodine-based processes that would reliably and effectively kill pathogenic virus, but no entirely satisfactory iodine-based process has hitherto been found. The term "pathogenic virus" is used here in its ordinarily understood sense to refer to a virus that is capable of causing disease in man or animal.

Many methods and materials exist for introducing iodine into blood fractions and products. Some of these methods and materials show great promise both in providing a high level of virucidal action and in acceptable protein function losses; nevertheless, results are not always consistent and variations in protein function are often great and inexplicable. It has, therefore, become apparent that the use of special methods and materials for introducing iodine into blood and blood products will not, alone, result in a reliable, virucidally effective method for treating such products with acceptable protein function loss.

In general, my work has corroborated the implications of the prior art, namely, that methods based on the use of iodine in blood and blood products are not, alone, satisfactory methods of preparing safe blood products. Iodine could be added by several methods using

several iodine source-compounds at such a level as to result in a complete kill of most virus; however, excessive losses of important protein functions, the clotting functions, for example, and degradation of the product occurred. I also explored in considerable depth the use of what I call the "capture" concept, namely the removal of iodine from the blood product after addition of the iodine for biocidal purposes. I determined that there was, in some instances, an advantage in removing the biocidal iodine within a relatively short period of time following addition; however, no entirely satisfactory removal system has heretofore been developed and results were not definitive or consistent. For example, it was known that povidone would "capture" iodine from solution and several forms of povidone were tested as capture materials. Such capture materials were not satisfactory, however, because of incomplete capture and re-iodination from the capture material. Re-iodination occurred when the capture material had absorbed iodine from the liquid being treated. This results in the release of iodine back into subsequent aliquots of such material as it passes through the capture material. Starch is, in theory, an effective capture material, but starch beds or columns tended to channel and/or clog.

The present invention is based on the discovery that a distinctive type of material does not channel or clog and substantially irreversibly captures iodine from biological liquids such as blood, blood fractions and derivatives.

Having experienced years of alternating hope and discouragement and many disappointments in research seeking to use the generally recognized biocidal effectiveness of iodine to treat

blood and blood derivatives and products, I have, I believe, discovered one solution to many of the problems predicted by earlier and contemporaneous workers, and which my earlier work established.

5

Summary of the Invention

I have discovered materials that are far more effective in removing iodine from blood and blood products, and other biological fluids, and, in some cases, iodide, than materials hitherto known for such applications. Very importantly, I have also found that the use of
10 very high efficiency "capture" materials to remove iodine from such fluids after only a very short contact with iodine or povidone iodine in such biological fluids results in a virucidally effective process without intolerable protein activity destruction.

The materials I have discovered can be made and used in the
15 form of particulate filter or column beds, fibrous beds, columns or bodies, or in any configuration that provides high surface area to contact the fluid to be treated.

A new device for treating liquids that comprise blood, blood fractions or blood derivatives or products is disclosed.

20 A new method for treating liquids that comprise blood, blood fractions or blood derivatives or products is disclosed.

Brief Description of the Drawing

Figure 1 is a schematic depiction of a device that embodies the invention disclosed herein.

25

Description of the Preferred Embodiments

Examples of the invention are provided to illustrate the various forms and applications in which the invention may be used. These are

exemplary only and not limiting.

In a very practical embodiment, of the type depicted schematically in Figure 1, the invention is a device for treating blood, blood plasma, and liquids comprising blood or a blood fraction or component in which blood or a blood fraction or component is a constituent. Typically, such biological liquids are handled in sterile bag systems that permit the liquid to be transferred from one container to another, additives to be incorporated therein, to be divided into components be, for example, expressing plasma through a filter while retaining cells in a container, etc. All this is well-known in the blood banking art. The present device is one component of such a system and may be placed in the system during manufacture, sterilized, stored and handled in the manner currently in practice. The illustrated embodiment of the invention comprises a liquid conduit system and a sponge, the sponge being so configured and constructed in relation to the conduit system as to permit the user to cause the liquid to be treated to pass through the sponge. It will be recognized that an infinite variety of sizes and shapes of the conduit system and sponge, which together comprise the capture system of this invention, are possible.

Referring to Figure 1, which is schematic only, the capture system comprises a liquid inlet 10, a housing 12, a liquid outlet 14 and a sponge 16. The system may, optionally, also include a bed of particles or other materials as a source of biocidal iodine, though this is not essential to the device as depicted in Figure 1.

The capture materials of this invention are identified hereinafter generally by the term "polyvinyl acetate-alcohol-acetal porous body."

This term, "polyvinyl acetate-alcohol-acetal porous body," is adopted as being as descriptive as any term available but is not a term that has, to the best of my knowledge, a generally accepted meaning in polymer chemistry. By referring to a material as a polyvinyl acetate-
5 alcohol-acetal porous body I mean a material that meets the following criteria. The material will comprise a polymer in which the long chain polymeric structure results substantially from vinyl polymerization and in which substituents along the long chain polymeric structure substantially comprise one or more of the following substituent
10 moieties: acetate, alcohol or acetal. Of course, the material must not be soluble in water. The body may be integrally formed, e.g. as a single piece sponge, or fabricated, e.g. a fibrous body that is porous, or simply a body constrained by internal or external structures, e.g. a bed of particles or a frit formed of such particles. For example, a frit
15 can be prepared by pressing a body of particles of polyvinyl acetate, polyvinyl acetal or polyvinyl alcohol, of highly uniform size, with or without the addition of heat and/or a poor solvent. The particular nature of the body is retained insofar as surface area for contact is concerned, but the frit is in the desired fixed configuration and is not
20 subject to channeling or clogging with particle fines. The body must, however, be highly porous. Thus far, no great criticality as to pore or passage size has been identified but a pore or passage size in the range of 1 to 1000 microns, typically from 10 to 100 microns, is presently considered to be acceptable for most uses under
25 consideration.

In a more specific sense, particularly in referring to preferred embodiments, the polyvinyl acetate-alcohol-acetal porous body is

preferably a biocompatible, polymeric, elastomeric, lint-free, hydrophilic sponge or fibrous body having a generally uniform pore or passage geometry and pore or passage size distribution throughout its volume comprising polyvinyl acetate polymer, polyvinyl acetate-
5 alcohol copolymer or the reaction product of formaldehyde and polyvinyl alcohol. The sponge or fibrous body is characterized by an initial water absorption and a wicking point of a maximum of 10 seconds of contact with the body fluid and by a variation in the size of the diameter of the pores of less than about 8 to 1.

10 While manufacturing methods are not part of this invention, the materials of this invention are typically manufactured by the steps of, first, forming a polymer or copolymer of vinyl acetate, followed by partial hydrolysis of the polymer to the alcohol, or partial or complete hydrolysis followed by acetalization.

15 Generally, the materials identified as polyvinyl acetate-alcohol-acetal porous bodies will be acceptable for use in contact with biological materials if FDA approved catalysts, etc., are used in the various manufacturing steps.

20 The preferred capture material is a sponge of the type sold by Merocel Corporation as Merocel® sponge, the characteristics and method of manufacture are described in U.S. Patent No. 4,098,728 to Rosenblatt, which is a uniformly expandable hydrophilic sponge, adapted for medical usage, characterized by instantaneous wicking and a high liquid holding capacity comprising a reaction product of
25 polyvinyl alcohol and formaldehyde. The wicking and liquid holding capacity is attained by controlling the time, temperature and processing conditions while forming and curing the reaction product

in an aqueous medium. The sponge is rendered uniformly expandable by drying the wet sponge while maintaining the shape of the wet sponge. The sponge is biocompatible, non-toxic, lint free, compressible, resilient, strong, non-abrasive, free of foreign leachable materials and is of exceptionally high fluid holding capacity.

Reference is made to U.S. Patent 4,098,728, the disclosure of which is incorporated herein by reference, for further details as to the manufacture of the sponges. In addition, further specifics are available from the manufacturer.

For purposes of identifying such sponges, Rosenblatt's definition is adopted herein, as follows: " A biocompatible, polymeric, elastomeric, lint-free, uniformly swellable hydrophilic sponge having a uniform pore geometry and pore size distribution throughout its volume comprising the inorganic acid-catalyzed reaction product of formaldehyde and polyvinyl alcohol, said sponge being characterized by an initial water absorption and a wicking point of a maximum of 10 seconds of contact with the body fluid and by a variation in the size of the diameter of the pores of less than about 8 to 1 as determined by a stereoscopic microscope eyepiece."

The sponge as described has been found to be unique in its avidity for iodine coupled with the near-irreversible nature of iodine uptake from biological solutions. By comparison, povidone is known to have a high avidity for iodine and to have a high iodine loading capacity, but povidone has proven to be less satisfactory as a capture material. Capture, by povidone, is either incomplete or ineffective because, it is believed, povidone binding of iodine is slower than the binding of iodine to the PVAc materials of the present invention, and

also because povidone begins to reintroduce iodine into the solution once modest amounts of iodine have been taken up. Contrariwise, Merocel® sponges, when initially free of iodine, take up iodine rapidly and completely. Certainly it would be expected that a highly iodine loaded sponge would constitute a source of iodine — indeed this is known to be the case — the iodine uptake is substantially irreversible until iodine levels in the range of above two or three weight percent are reached. The capture systems of this Invention use such sponges that are initially free of iodine.

10 This iodine capture material is vastly superior to any previously known capture material. These sponges instantly bind iodine essentially quantitatively, unlike the action of polyvinyl pyrrolidone wherein the iodine uptake is very equilibrium dependent and the binding reaction is comparatively slow. The affinity of the sponges for iodine is far greater than the affinity of polyvinyl pyrrolidone; indeed, these sponge materials readily extract iodine from povidone iodine. The affinity of these sponge materials is comparable to the affinity of starch for iodine, though specific quantitative values have not yet been ascertained. Because the uptake of iodine is fast, instantaneous, and irreversible, and because the sponge does not permit channeling nor contribute fines, it is a very superior capture material — surprising superior as to the iodine uptake characteristics which could not have been and had not been predicted.

25 Iodine uptake from water is one measure of the sponge's superiority, but such data are not entirely definitive as to biological materials. Iodine in water is present as dissolved iodine, iodide or I_3^- ; whereas iodine in a biological fluid may be present in these three

forms and may be bound, more or less strongly, to any of a large number of cells, proteins, etc. Much remains to be learned about the iodine uptake mechanism from biological fluids but the great superiority of the sponge material has been established.

5 The invention in this preferred embodiment, then, is embodied in an iodine capture system that comprises a biological liquid conduit and, disposed therein, a biocompatible, polymeric, elastomeric, lint-free, uniformly swellable hydrophilic sponge having a uniform pore geometry and pore size distribution throughout its volume comprising
10 the inorganic acid-catalyzed reaction product of formaldehyde and polyvinyl alcohol, said sponge being characterized by an initial water absorption and a wicking point of a maximum of 10 seconds of contact with the body fluid and by a variation in the size of the diameter of the pores of less than about 8 to 1 as determined by a stereoscopic
15 microscope eyepiece.

 Other forms of the polyvinyl acetate-alcohol-acetal porous body of this invention may be used. For example, a sponge can be made from polyvinyl acetate or polyvinyl acetate-alcohol copolymer using a froth technique such as described by the Rosenblatt patent referred to
20 above. Polyvinyl acetate sponges will be moderately hydrophilic and rather rigid and brittle, whereas polyvinyl acetate-alcohol sponges will be more hydrophilic, water swellable and more flexible. Likewise fibers can be spun using conventional fiber spinnerettes and the resulting fibers physically formed into a porous body as characterized
25 above. Thin films of polyvinyl acetate or copolymers of polyvinyl acetate-alcohol may be cast as flat or curved films and re-formed, bundled together in proximity to provide flow paths between the

grouped films or comminuted and the particles re-formed or confined to form such porous bodies.

Materials that are closely related chemically to the polyvinyl acetate-alcohol-acetal porous bodies of this invention have been used in a variety of biologically related applications. The following uses of related materials, gleaned from literature and patent abstracts, is considered exemplary and illustrative of such uses. Tan, J.H.; et al, (Radiation Research, vol.124, no.1, p.43-9, Oct. 1990) implanted a polyvinyl alcohol sponge disc in the subcutis of the thorax. Criswell, D. W. et al, (Armed Forces Inst. of Pathology, Washington, DC., Report No.: AFOSR-TR-92-0910) implanted polyvinyl alcohol sponge in mouse subcutaneous tissue to investigate intermittent hyperoxia oxygen treatments and epidermal growth factors. A study of photocrosslinkable polyvinyl alcohol for bioreactors was reported in Bulletin of Research Institute for Polymers and Textiles, No. 162, 1990-3, Research Inst. for Polymers and Textiles, Yatabe (Japan). Leukocyte filters from polyvinyl alcohol fibers has been reported by Tan, J.H., (Conference Title: Proceedings of the 11th Congress of the International Society for Artificial Cells, Blood Substitutes and Immobilization Biotechnology, (ISABI), *Biotechnology* 22 5 Nov 1994, p A64). Sakurada Y., et al, (*Polym.J.(Jap.)*; 19, No.5, 1987, p.501-13) describe hollow fibre membranes having blood filtering characteristics and applications to blood purifying devices by spinning polyvinyl alcohol and poly(alkylene glycol) in water into a coagulation bath of sodium hydroxide/sodium sulphate. Abe Y, et al., (CONFERENCE PROCEEDINGS: Plasmapheresis: New trends in therapeutic applications; Cleveland, Ohio, 25-26 April 1983, p.295-304. 6S) describes the use of polyvinyl alcohol membranes in plasmapheresis-like applications. A separating agent which includes a

polyvinyl acetal resin having open cell structure and an average pore size of from about 10 to about 1000 micrometers has been described by Hiraide Tsuneo et al, (US Patent No. 5085781). The device also includes porous calcium phosphate granules having open cell structure. Japanese patent no. JP 7025776 describes a filter material made of porous element coated with a polymer having both hydrophobic and polyethylene oxide (PEO) chain parts on the surface and is used for filtration of blood to screen leukocytes. Porous spongy filter elements e.g. polyvinyl alcohol sponges with average fibre sizes of 0.3-3.0 microns and average pore sizes of 2-30 microns are coated with a polymer having hydrophobic part and PEO chain (e.g. methoxytriethylene or hydroxypolyethylene glycol, acrylic acid esters) part. The selective removal of leukocytes to give platelet enriched plasma followed by selective recovery of platelets for blood transfusion or extracorporeal circulation are accomplished. Shevel, E., US Patent No. 5370656 (owned by Merocel Corporation) describes a throat sponge made from polyvinyl acetal that is fast working and expands instantly and uniformly to absorb 23 to 27 times its weight in fluids. The sponge may be pre-hydrated., Polyvinyl alcohol polymers have been studied as a possible support matrix for affinity chromatography in connection with viscous material (e.g., blood plasma), (KANG K; RYU D; DROHAN WN; ORTHNER CL, *BIOTECHNOLOGY AND BIOENGINEERING*, 1992, V39, N11 (MAY), P1086-1096).

The invention is, in use, embodied in the method of removing iodine from biological liquids comprising passing such liquid(s) through a substantially iodine free biocompatible, polymeric, elastomeric, lint-free, uniformly swellable hydrophilic sponge having a uniform pore geometry and pore size distribution throughout its

volume comprising the inorganic acid-catalyzed reaction product of formaldehyde and polyvinyl alcohol, said sponge being characterized by an initial water absorption and a wicking point of a maximum of 10 seconds of contact with the body fluid and by a variation in the size of the diameter of the pores of less than about 8 to 1 as determined by a stereoscopic microscope eyepiece. A substantially iodine-free sponge contains less than one percent by weight of iodine.

In another aspect, the invention comprises a method embodying two steps. The first step is the addition of iodine to the biological fluid. The second step is the capture of any residual iodine by the sponge as described. Figure 1 depicts a source of iodine at 18. This is optional, of course, but in some processes it is advantageous to control the contact time of the biological fluid with iodine by positioning the iodine source in the overall liquid handling system and controlling the flow of liquid therein. In the exemplary embodiment of Figure 1, insoluble povidone iodine (cross-linked povidone - iodine) is provided at 18. The amount and concentration of iodine may, of course, be adjusted as needed sufficient to effect a kill of virus or bacteria, etc., as desired, and, immediately thereafter, preferably within one to five minutes, most preferably under two minutes, passing the iodinated liquid through the capture sponge where the iodine is removed. This technique greatly reduces alteration of proteins and preserves the very labile clotting factors. Over 80% of the available clotting factors can be protected while effecting a complete kill of envelope and non-envelope virus by adjustment of the amount of iodine available and the time of iodine contact with the liquid to be treated.

Biological liquids include, of course, blood, plasma, serum, etc.

as well as special solutions containing clotting factors or other blood proteins, cell suspensions and concentrates, and the like.

Pore size of the sponges may be controlled to produce sponges that will effectively separate platelets from liquid blood components.

5 This, in itself, greatly enhances the recovery of valuable blood proteins. On the other hand, large pore size sponges may be used to treat whole blood, platelet-containing liquids, etc.

Example 1

Conventional filter funnels were prepared using the polyvinyl acetate-alcohol-acetal porous bodies of this invention. The filter funnel comprises a chamber directly overlaying a filter. The filters were polyvinyl acetal as described above that is commercially available in sheets under the trademark MEROCEL CF 200® and MEROCEL CF 150®. Blood plasma containing EMC virus (encephalomyo-carditis virus) was divided into four aliquots as described below and passed through the polyvinyl acetal filter sponge within one minute \pm about 30 seconds following mixing. Layers of sponge, one or two layers as indicated below, about 1/4 inch thick were used. The amount of two clotting factors, Factor VIII and Factor IX, remaining after the treatment was measured, using the known amount of these factors present before the treatment as the base line. The respective aliquots and the results of this series of tests are given in Table I below, first two entries, along with summary results of a number tests run at different times without capture.

10
15
20

TABLE I

	<u>Aliquot</u>	<u>EMC Kill</u> <u>(Log Kill)</u>	<u>% F VIII</u> <u>(% Remaining)</u>	<u>% F IX</u> <u>(% Remaining)</u>
5	Control	0	100	100
10	2% (by weight) povidone-iodine + 2 % (by weight) Povidone passed through two layers of polyvinyl acetal capture sponge.	Total	85	75
15	Povidone iodine 0.5 to 5.0 weight percent in plasma, in various tests.	Total	>50	>50

20 In many of the tests summarized in the third entry, virtually all of the Factor VIII and/or Factor IX activity was lost, and losses of 60% or more were common.

Beds formed of polyvinyl acetate beads take up iodine and experience with hydrolyzed then acetalized polyvinyl acetate provide sound basis for knowing that polyvinyl acetate-alcohol is an equivalent material.

25 The exact time progression of clotting factor destruction in the presence of iodine is a function of iodine concentration and is believed to be a function of pH and perhaps of temperature and other factors not yet determined. While this time function is not fully understood, it has been established that the contact time of the iodine in blood, plasma, solutions of clotting factors, etc., and other biological solutions comprising labile proteins must be kept to under five minutes and, in most circumstances, must be kept to under two minutes, if

30

labile proteins, clotting factors, etc., are to be preserved.

Capture of the iodine must, of course, be substantially instantaneous and must be certain. Other capture materials have been evaluated. Starch is well-known to react substantially quantitatively with iodine; however, starch beds and even specially prepared starch or amylose beds or columns clog quickly and/or channel and give uncertain results. Povidone is a moderately good capture material but its uptake is slow and it quickly reaches the point where iodine begins to migrate back into the liquid phase. The presence of and generation of fine particles during use is a continuing problem. While this "leaking" of iodine can be overcome to some degree by using deep beds or long columns of insoluble povidone particles, there is nevertheless some continuing iodination of the liquid with resulting loss of functional clotting factors, etc. The polyvinyl acetate-alcohol-acetal porous bodies provide substantially instantaneous quantitative uptake of iodine, no iodine leakage at low levels of iodine uptake, and a free-flowing filter or column construction.

Sponges of the type described are available in a variety of pore sizes and can be made with pores averaging nearly any reasonable size. Such sponges can be used, for example, to treat whole blood wherein all of the blood, including the cells, pass through the sponge.

Sponges having a smaller pore size, generally in the range of 2 to 30 microns, e.g. under 10 microns, typically 2-3 microns, may, on the other hand, be used to remove all cellular materials, most particularly platelets, from blood leaving a blood serum-like liquid in which the clotting factors are better preserved than is the case when platelets

are present. While Japanese patent no. JP 7025776, according to the abstract thereof, describes a filter material made of porous element coated with a polymer having both hydrophobic and polyethylene oxide (PEO) chain parts on the surface used for filtration of blood to screen leukocytes, no direct use of
5 polyvinyl acetate-alcohol-acetal porous bodies to remove platelets from plasma has been reported. This step can, of course, be carried out while inactivating virus.

Thus, a new and very important result is accomplished by this invention. Contrary to the prior art teachings and my own extensive
10 earlier work, it is now possible to treat blood and blood fractions, products and derivatives with iodine to effect a complete kill of pathogenic virus without loss of the important blood protein functions. Hundreds of millions of dollars have been spent in efforts to provide safe blood and blood constituents without success. This invention
15 makes it possible to achieve the goal that for decades has eluded workers in the blood banking and fractionation industries.

Industrial Application

This invention is useful in the blood banking and blood fractionation industries and in the biotechnology industries generally.

CLAIMSWhat Is Claimed Is:

1. An iodine capture system comprising a liquid conduit and, disposed therein, a biocompatible, polymer formed by the inorganic acid-catalyzed reaction of formaldehyde and polyvinyl alcohol.
2. A method for removing iodine from a biological liquid and
5 from protein dissolved in said liquid comprising the step of passing said liquid through a substantially iodine free biocompatible, polymer formed from the inorganic acid-catalyzed reaction of formaldehyde and polyvinyl alcohol.
3. A method for treating biological fluids or protein-containing solutions comprising the steps of:
10 adding iodine to the biological fluid or protein-containing solution to be treated; and
passing said fluid or said solution through a substantially iodine-free biocompatible, polymer formed as the inorganic acid-catalyzed reaction product of formaldehyde and polyvinyl
15 alcohol to remove iodine from said fluid or said solution.
4. An iodine capture system for removing iodine from a liquid comprising a liquid conduit and, disposed therein, a polyvinyl acetate-alcohol-acetal porous body.
5. A method for removing iodine from biological fluids or
20 protein-containing liquids comprising passing said fluids or liquids through a substantially iodine free polyvinyl acetate-alcohol-acetal porous body.


6. A method for treating biological fluids or protein-containing liquids comprising adding iodine to the biological fluids or protein-containing liquids to be treated and thereafter capturing residual iodine by passing the iodine-containing biological fluid or protein-containing liquid through a substantially iodine free polyvinyl acetate-alcohol-acetal porous body.

7. A method for treating platelet containing fluids comprising the steps of
adding iodine to the platelet containing fluid; and
passing the iodine-containing fluid through a substantially iodine free biocompatible, porous polymeric body formed from the inorganic acid-catalyzed reaction of formaldehyde and polyvinyl alcohol to capture residual iodine resulting in a substantially iodine-free platelet containing liquid.

8. The method of Claim 7, wherein the porous polymeric body has a majority of pores with an average diameter of 2-3 μm .

9. A method for treating platelet containing fluids comprising the steps of
adding iodine to the platelet containing fluid; and
passing said iodine-containing fluid through a substantially iodine free, porous polyvinyl-alcohol-acetal body to capture residual iodine resulting in a substantially iodine-free platelet containing liquid.

10. The method of Claim 7, wherein the porous polyvinyl-alcohol-acetal body has a majority of pores with an average diameter of 2-3 μm .

*FIG. 1*

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/18604

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61L2/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	US 5 589 072 A (SHANBROM EDWARD) 31 December 1996 see the whole document ---	1-10
Y	EP 0 391 741 A (MEROCEL CORP) 10 October 1990 see claims ---	1-10
Y	WO 93 21933 A (SHANBROM EDWARD) 11 November 1993 see claims ---	1-10
A	WO 93 17693 A (SHANBROM EDWARD) 16 September 1993 see claims --- -/--	1-10

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- * "A" document defining the general state of the art which is not considered to be of particular relevance
- * "E" earlier document but published on or after the international filing date
- * "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- * "O" document referring to an oral disclosure, use, exhibition or other means
- * "P" document published prior to the international filing date but later than the priority date claimed

- * "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- * "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- * "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * "&" document member of the same patent family

Date of the actual completion of the international search

24 July 1997

Date of mailing of the international search report

31.07.1997

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

ESPINOSA, M

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/18604

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	W0 93 04678 A (SHANBROM EDWARD) 18 March 1993 & US 5 370 869 A cited in the application ---	
A	W0 93 04731 A (SHANBROM EDWARD) 18 March 1993 & US 5 360 605 A cited in the application -----	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/18604

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5589072 A	31-12-96	NONE	
EP 0391741 A	10-10-90	AT 121266 T CA 2014114 A DE 69018684 D DE 69018684 T JP 2299662 A US 5071648 A	15-05-95 06-10-90 24-05-95 28-09-95 11-12-90 10-12-91
WO 9321933 A	11-11-93	EP 0614368 A JP 6509118 T	14-09-94 13-10-94
WO 9317693 A	16-09-93	EP 0591483 A JP 6511013 T	13-04-94 08-12-94
WO 9304678 A	18-03-93	US 5370869 A EP 0559856 A JP 6505503 T	06-12-94 15-09-93 23-06-94
WO 9304731 A	18-03-93	US 5609864 A US 5360605 A	11-03-97 01-11-94